This federal contract award, identified as SPE2DB24D8001 and SPE2DB25FKYUT, was granted by the Defense Logistics Agency (DLA) to the prime contractor Dakota Drug, Inc., a self-certified small disadvantaged business. The contract, valued at $6,602.12, is for the delivery of the pharmaceutical product ACTEMRA ACTPEN 162 MG/0.9 ML 0.9ML. This award is not associated with a set-aside program and is a firm fixed price, delivery order contract type. Dakota Drug, Inc. has a significant Indefinite Delivery Contract (IDC) with the DLA, valued at $999,999,999.00, which allows the company to provide a comprehensive range of pharmaceutical products, medical supplies, and healthcare equipment to support U.S. Armed Forces medical operations. This contract, part of the DLA Troop Support Medical's ECAT Generation V Program, has a performance period extending through December 31, 2025.
Generated 2/3/25, 1:43 PM